Research
Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing
-
* Corresponding author: Salvatore Coppolino sacoppolin@yahoo.it
- † Equal contributors
1 U.O.C. Pediatria e UTIN, P.O. "Barone I. Romeo", Via Mazzini, Patti, Messina (98066), Italy
2 Dipartimento del Farmaco, Cittadella della Salute, Viale Giostra, Messina (98100), Italy
3 Servizio di Farmacia, P.O. "Barone I. Romeo", Via Mazzini, Patti, Messina (98066), Italy
Italian Journal of Pediatrics 2010, 36:48 doi:10.1186/1824-7288-36-48
Published: 7 July 2010Abstract
Background
Respiratory syncytial virus is the most important pathogen in lower respiratory tract infection in infants and young children. In high-risk populations it may develop severe, sometimes fatal, lower respiratory tract infections. A proportion of these infants require admission to intensive care units due to the severity of the condition and the level of care needed. Furthermore, we must consider the possible increased risk of asthma following RSV infection in infancy.
Methods
The aim of this work is to show how we strictly coordinated, during the 2008-2009 RSV season, the delivery of prophylaxis while minimising drug cost through vial sharing and cohorting infants with a software performed through Visual Basic programming system.
Results
By using this method we have been able to obtain a saving of the 29.2% compared to the theoretical amount. No infant requested hospitalisation for a RSV infection.
Conclusions
Such a model ensures all patients to receive appropriate immunization and thus positively influencing the cost-benefit of palivizumab prophylaxis. We hope that our model of care delivery will be of use to other hospitals.